Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancer

Most patients with advanced non-small cell lung cancer (NSCLC) do not achieve a durable remission after treatment with immune checkpoint inhibitors. Here we report the clinical history of an exceptional responder to radiation and anti-program death-ligand 1 (PD-L1) monoclonal antibody, atezolizumab,...

Descripción completa

Detalles Bibliográficos
Autores principales: Coffey, David G., Xu, Yuexin, Towlerton, Andrea M. H., Kowanetz, Marcin, Hegde, Priti, Darwish, Martine, Yadav, Mahesh, Blanchette, Craig, Ruppert, Shannon M., Bertino, Sarah, Xu, Qikai, Ferretti, Andrew, Weinheimer, Adam, Hellmann, Matthew, Qin, Angel, Thomas, Dafydd, Warren, Edus H., Ramnath, Nithya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500393/
https://www.ncbi.nlm.nih.gov/pubmed/36159875
http://dx.doi.org/10.3389/fimmu.2022.961105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500393/
https://www.ncbi.nlm.nih.gov/pubmed/36159875
http://dx.doi.org/10.3389/fimmu.2022.961105

Ejemplares similares